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Introduction: The appreciable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to
lower generic prices and enhance their utilization. However, considerable variation in their use and prices.
Objective: Assess the influence of multiple supply and demand-side initiatives across Europe for established medicines
to enhance prescribing efficiency before a decision to prescribe a particular medicine. Subsequently utilize the findings
to suggest potential future initiatives that countries could consider.
Method: An analysis of different methodologies involving cross national and single country retrospective observational
studies on reimbursed use and expenditure of PPIs, statins, and renin-angiotensin inhibitor drugs among European coun-
tries.
Results: Nature and intensity of the various initiatives appreciably influenced prescribing behavior and expenditure, e.g.,
multiple measures resulted in reimbursed expenditure for PPIs in Scotland in 2010 56% below 2001 levels despite a
3-fold increase in utilization and in the Netherlands, PPI expenditure fell by 58% in 2010 vs. 2000 despite a 3-fold increase
in utilization. A similar picture was seen with prescribing restrictions, i.e., (i) more aggressive follow-up of prescribing
restrictions for patented statins and ARBs resulted in a greater reduction in the utilization of patented statins in Austria
vs. Norway and lower utilization of patented ARBs vs. generic ACEIs in Croatia than Austria. However, limited impact of
restrictions on esomeprazole in Norway with the first prescription or recommendation in hospital where restrictions do
not apply. Similar findings when generic losartan became available in Western Europe.
Conclusions: Multiple demand-side measures are needed to influence prescribing patterns. When combined with
supply-side measures, activities can realize appreciable savings. Health authorities cannot rely on a “spill over” effect
between classes to affect changes in prescribing.
Keywords: demand-side measures, drug utilization studies, generics, PPIs, renin-angiotensin inhibitor drugs, statins
INTRODUCTION
Pharmaceutical expenditure is under increasing scrutiny, with
expenditure rising by more than 50% in real terms during the
past decade among OECD countries (Godman et al., 2013a).
As a result, pharmaceutical expenditure has become the largest,
or equaling the largest, cost component in ambulatory care and
in some countries up to 60% of total healthcare expenditure
(Godman et al., 2012a, 2013a). This will continue unless actively
addressed, driven by well-known factors including ageing pop-
ulations, rising patient expectations and the continued launch of
new premiumpriced technologies (Garattini et al., 2008; Godman
et al., 2013a).
KEY CONCEPT 1 | Pharmaceutical expenditure
Pharmaceutical expenditure is under increasing scrutiny among health
authorities, which is already resulting in some countries unable to fund
new premium priced drugs. Potential ways forward include demand-side
measures to encourage the preferential prescribing of low cost gener-
ics where care is not compromised, including addressing concerns with
generics where these exist.
We are already seeing some countries unable to fund new pre-
mium priced drugs due to continued pressures. If not addressed,
the number of countries is likely to grow with prices of new drugs,
including new biological drugs, typically between US$100,000–
US$400,000 per patient per year or more (Experts in chronic
myeloid leukemia, 2013; Godman et al., 2013a; Malmström et al.,
2013). Measures for new drugs include instigating models to
optimize their managed entry, starting pre-launch and contin-
uing post-launch (Malmström et al., 2013). They also include
the development of managed entry agreements to enhance the
value of new drugs, and hence potential funding, as well as reg-
istries post-launch to assess the effectiveness and safety of new
drugs in routine clinical care (Klemp et al., 2011; Ferrario and
Kanavos, 2013; Malmström et al., 2013). Greater discussion of
these activities including their rationale are outside the scope of
this article.
Measures for established drugs include initiatives to increase
the prescribing of low cost generic drugs vs. originators and
patented products in a class where all products in the class
or related class are seen as essentially therapeutically similar
in all or nearly all patients. As a result, considerable savings
can be achieved without compromising care (Bennie et al.,
2012; Godman et al., 2012a, 2013a). The savings are facilitated
by annual global sales of pharmaceutical products losing their
patents between 2008 and 2013 estimated at US$50 to 100 billion
(C35–70). This rises to US$255 billion between 2011 and 2016
(Godman et al., 2012a, 2013b). There are also central procure-
ment initiatives among countries to conserve resources. These
include a public tendering system for simvastatin in Belgium,
two-weekly assessments of prices for multiple sourced products
in Denmark, monthly auctions for generics in Sweden and up
to yearly tenders in the Netherlands (Dylst et al., 2011, 2013;
Fraeyman et al., 2013; Godman et al., 2013a).
Demand-side measures to enhance the prescribing of generics
vs. originators and patented products in a class include educa-
tional activities, prescribing targets, financial incentives including
patient co-payment differentials, compulsory International Non-
proprietary Name (INN) prescribing and prescribing restrictions
(Godman et al., 2012a, 2013a). This includes promoting generics
even when they are available initially as different salts to the
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originator with a lower number of indications once bioe-
quivalence has been demonstrated, e.g., generic clopidogrel
(Baumgärtel et al., 2012). In addition, setting minimum quotas
(in percentages) for physicians to encourage them to prescribe
low-cost medicines, e.g., Belgium (Fraeyman et al., 2013). Classes
where all products are seen as essentially therapeutically similar
include the proton pump inhibitors (PPIs), statins and renin-
angiotensin inhibitor drugs, with the latter including angiotensin
converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) (Weng et al., 2010; Wettermark et al., 2010;
Voncˇina et al., 2011; Godman et al., 2012a, 2013a; Moon et al.,
2010; Martin et al., 2014). As a result, patients can be switched
between treatments without compromising care (Usher-Smith
et al., 2008; Godman et al., 2011a,b, 2013b; Moon et al., 2010;
Martin et al., 2014). Consequently based on available evidence,
prescribing selection in these classes should primarily be based
on drug acquisition prices as the risks and benefits of different
choices should be similar at appropriate doses. As a result, educa-
tional activities should be aimed at promoting appropriate doses
and improving compliance, which can be poor in patients with
chronic diseases (Voncˇina et al., 2011; Bennie et al., 2012).
Alongside this, instigating a range of measures to address
physician and patient concerns with the effectiveness and/or
side-effects of generics can also be beneficial. Initiatives include
granting substitutability status for generics, publishing lists of
substitutable and non-substitutable products, not reimbursing
generics where there are concerns with their quality, physi-
cian and patient education, encouraging International Non-
proprietary Name (INN) prescribing as well as incentivizing
pharmacists to talk with patients when substituting or dispens-
ing different branded generics to allay fears and reduce confusion
(Godman et al., 2011a, 2012b; Olsson et al., 2014). Such initia-
tives have resulted in considerable savings as seen in France and
more recently in Portugal (Godman et al., 2012a,b).
A number of these strategies are aimed at counter-acting
the commercial activities of pharmaceutical companies, who
have typically been the principal source of pharmacotherapeutic
information among physicians for new and established drugs
(Godman et al., 2011a). Published studies suggest marketing costs
can be up to one third of a company’s income, with companies
spending US$53 billion (C40.2) in the US alone in 2004 market-
ing to physicians alongside lobbying and other indirect strategies
(Civaner, 2012; Malmström et al., 2013).
It is recognized that prescribing behavior is complex and that
there are different healthcare systems across Europe (Godman
et al., 2011a). However, countries need to learn from each
other to help maintain the European ideals of equitable and
comprehensive healthcare in the face of growing resource pres-
sures. We believe the plethora of different supply- and demand-
side measures introduced across Europe to enhance prescribing
efficiency will stimulate debates within countries on potential
additional initiatives to consider in the future. These can be
identified through either single country studies or cross national
comparisons of drug utilization and expenditure.
The objectives of this paper are to assess the influence of prin-
cipally demand-side reforms to enhance prescribing efficiency
in ambulatory care before a decision is made to prescribe a
particular drug within a class. Subsequently utilize the findings to
suggest potential future initiatives that countries could consider
to further enhance their prescribing efficiency.
METHODOLOGY
A number of methodologies were used. Firstly, a cross national
retrospective observational study of reimbursed utilization and
expenditure of the proton pump inhibitors (PPIs) and statins
among European countries between 2001 and 2007. These dates
were chosen as typically both generic simvastatin and generic
omeprazole became available and were reimbursed during this
time period among Western European countries (Godman et al.,
2011a). Simvastatin was the first major statin to become available
as a generic in Europe with generally no or limited utilization of
lovastatin. Omeprazole was the first PPI to become available as a
generic. Both events resulted in variable demand side initiatives to
try and enhance the prescribing of generics first line. In this study,
efficiency was broken down into three categories, summarized
in Table 1 (Godman et al., 2011a). The three cut-off points for
assessing efficiency were validated by health authority and health
insurance personnel across Europe (Godman et al., 2011a).
Secondly, single country retrospective observational studies in
Scotland (extended from 2007 to 2010), Belgium (1997 to 2009),
the Netherlands (2000 to 2010), and the Republic of Srpska (con-
stitutive entity of Bosnia and Herzegovina) (2003 to 2010) to
assess reimbursed utilization and expenditure for the PPIs and
statins (Bennie et al., 2012; Markovic-Pekovic et al., 2012; van
Woerkom et al., 2012; Fraeyman et al., 2013).
Thirdly, a cross national retrospective observational study
of reimbursed utilization and expenditure of ACEIs and ARBs
among 6 European countries between 2001 and 2007. During
this time, multiple measures were introduced by some countries
to limit the prescribing of patented ARBs vs. lower cost generic
ACEIs (Voncˇina et al., 2011). The findings were also compared
with the influence of prescribing restrictions for the ARBs in the
Republic of Srpska (Markovic-Pekovic et al., 2012).
Only administrative databases were used in the various stud-
ies to provide accurate data on reimbursed utilization and
expenditure (Godman et al., 2011a). As a result, only data on
ambulatory care utilization and expenditure data was recorded.
This typically includes out-patient but not in-patient data. In all
cases, utilization rates were computed using Defined Daily Doses
(DDDs) in line with international guidance (WHO, 2003). The
latest DDDs were also used, again in line with recommendations
(WHO, 2003; Godman et al., 2011a). We did not use Prescribed
Daily Doses (PDDs) as there was no access to patient data in the
majority of countries studied.
The findings will be supplemented by recently published
studies following the availability of generic losartan among
the ARBs and generic risperidone among the atypical antipsy-
chotics (Godman et al., 2012b, 2013c,d,e; Martin et al., 2014).
The objective is to provide additional guidance to health
authorities.
Demand side measures have typically been collated under
the “4 Es,” i.e., education, engineering, economics, and enforce-
ment. Examples and definitions include (Wettermark et al., 2009;
Godman et al., 2011a):
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Table 1 | Principal measures used to evaluate changes in prescribing efficiency for both the PPIs and statins during the study years as well as
categorize countries (Godman et al., 2011a).
Objective Measure Efficiency criteria/comment
Assessment of overall
prescribing efficiency
The increase in utilization rates
vs. the increase in reimbursed
expenditure over time*
3 efficiency criteria:
No efficiency—rate of increase in expenditure exceeds utilization
Efficient countries—rate of increase in utilization more than double the rate of increase in
expenditure
Very efficient countries—reimbursed expenditure decreasing over time despite increasing
utilization. In the case of statins this also includes considerably increased utilization (over
350% during the study period) with only a limited increase in expenditure (20% or less)
Extent of potential
savings from increasing
prescribing efficiency
Overall utilization in 2007
(DDD/DID) compared with
overall expenditure (€/1000
inhabitants/year), with both
measures adjusted for
population sizes
Data treated with caution as different co-payment levels for the PPIs and statins in
addition to any co-payment for the package
*NB Generic PPIs and statins were often available in Central and Eastern European countries before 2001 influencing the figures. The figures for the Republic
of Ireland are distorted by the fact that the GMS population has a greater morbidity than the general population reflected in appreciably higher utilization of
pharmaceuticals.
• Educational activities—includes development and distri-
bution of prescribing guidance right through to more
intensive strategies including educational outreach visits and
benchmarking of physician prescribing habits.
• Engineering activities—includes organizational or manage-
rial interventions such as prescribing targets as well as price:
volume agreements for single sourced existing products.
• Economic interventions—includes devolved budgets with
penalties, positive and negative financial incentives for
physicians, as well as differential patient co-payments for more
expensive products than the current reference molecule.
• Enforcement—includes regulations by law such as mandatory
generic substitution and compulsory INN prescribing as well
as prescribing restrictions.
Reimbursed expenditures were typically captured reflecting the
payer perspective of the various studies. The only exceptions were
Austria, Germany, and Norway where there are difficulties with
disassociating co-payments from total expenditure (Godman
et al., 2011a). However, this typically represented only a small
proportion of overall expenditure in these three countries.
Expenditure data was generally collected in local currency and
converted to Euros where pertinent based on the established con-
version rates for the country; alternatively an average for the
year from national banks (Godman et al., 2011a; Voncˇina et al.,
2011).
There was generally no allowance for inflation in order to
directly compare the impact of the different policies over time.
In addition, health authorities typically refer to pre-patent loss
prices when establishing reimbursed prices for generics (Godman
et al., 2010a, 2011a,b; Voncˇina et al., 2011).
No attempt was made to analyze the appropriateness of pre-
scribing due to the lack of access to patient databases. In addition,
the main emphasis of the various studies was on prescribing
efficiency once a decision had been made by the physician to pre-
scribe either a PPI, renin-angiotensin inhibitor drug or a statin.
As a result, care should not be compromised through encouraging
the greater use of generics at appropriate doses (Norman et al.,
2008; Usher-Smith et al., 2008; Moon et al., 2010; Godman et al.,
2013a; Martin et al., 2014).
RESULTS
PPIs AND STATINS 2001 TO 2007
The influence of the different initiatives in terms of their extent
and intensity can be seen in Figure 1 (for the PPIs—similar for
the statins) (Godman et al., 2011a). The countries were broken
down by:
• Geography—into Central and Eastern European countries and
the rest. This is because generic PPIs were generally available
earlier in Central and Eastern European countries thanWestern
European countries reducing potential efficiency gains.
• The different approaches to pricing of generics—
Prescriptive—PP, Market Forces—MF, Mixed—MA (Box 1)
(Godman et al., 2010a).
Countries showing considerable prescribing efficiency, as well as
general efficiency, i.e., below the line drawn, are highlighted using
the definitions listed in Table 1.
The differences seen in the rates of prescribing efficiency for
the both the PPIs and statins between 2001 and 2007 among the
various European countries (Figure 1 with similar findings for
the statins) were also reflected in considerable differences in over-
all expenditure in 2007 adjusted for population sizes (Figure 2
KEY CONCEPT 2 | PPIs and statins
Multiple and intensive demand-side measures are needed to enhance the
prescribing of generic PPIs and statins. Multiple measures resulted in con-
siderable efficiency savings in some European countries with the products
in both classes seen as therapeutically similar at appropriate doses in all or
nearly all patients. Expenditure/1000 inhabitants/year in Sweden in 2007 was
less than one tenth of that seen in the Republic of Ireland, although greater
co-morbidity among the patients in Ireland.
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with similar findings for the PPIs). The differences in geog-
raphy and approaches to the pricing of generics have again
been highlighted, with overall expenditures affected by whether
there are high co-payment levels for the statins (Godman et al.,
2011a).
Among the Western European countries, expenditure/1000
inhabitants/year in Sweden in 2007 for both the PPIs and statins
(Figure 2) with their multiple measures was less than one tenth of
that seen in the Republic of Ireland at over C60,000/1000 inhab-
itants/year (Godman et al., 2010b). However, there was greater
morbidity among the selected population in Ireland (Godman
et al., 2010b, 2011a).
PPIs AND STATINS IN BELGIUM, THE NETHERLANDS, THE REPUBLIC
OF SRPSKA, AND SCOTLAND
Belgium
Multiple reforms including co-payments and reference pricing
appreciably enhanced rational prescribing for both the PPIs and
statins following generic availability (Fraeyman et al., 2012, 2013).
In a recent study, there was an 8-fold increase in PPI utilization
between 1997 and 2009 but only 2-fold increase in reimbursed
expenditure, helped by decreasing expenditure/DDD for the PPIs
from C1.91 in 1997 to C0.52 in 2009. Similarly, a 20-fold increase
FIGURE 1 | Rate of increase in expenditure (local currency) vs. the rate
of increase in utilisation (DDD based) for the PPIs principally from 2001
to 2007 among European countries (unless stated), with generic
pricing approaches divided into three categories (Godman et al.,
2011a). NB: Generic pricing: PP, Prescriptive pricing; MF, Market Forces;
MA, Mixed Approach (Box 1). Standard EU country abbreviations have been
used. ES = Catalonia (2007 vs. 2003), EE = 2007 vs. 2004, HR = 2007 vs.
2000, IT = 2008 vs. 2006, NO = 2007 vs. 2004; TR = 2009 vs. 2007.
in statin utilization between 1997 and 2009 but only a 5-fold
increase in reimbursed expenditure, helped again by reimbursed
expenditure/DDD decreasing from C2.05 in 1997 to C0.57 in
2009 (Fraeyman et al., 2013).
The Netherlands
Multiple demand-side measures including education, engineer-
ing, economics, and enforcement (statins) encouraging the pref-
erential prescribing of generic PPIs and statins resulted in (van
Woerkom et al., 2012):
• Reimbursed expenditure for the PPIs fell by 58% in 2010
vs. 2000 despite a 3-fold increase in utilization, helped by
increasing utilization of generic omeprazole at only 2% of the
pre-patent loss price. The low price for generic omeprazole in
the Netherlands was helped by the instigation of a preference
pricing policy for multiple sourced products.
• Reimbursed expenditure for the statins fell by 14% in 2010 vs.
2000 despite a 3.8-fold increase in utilization. Again helped by
increasing utilization of generic simvastatin at only 2% of the
pre-patent loss originator price.
The Republic of Srpska
Multiple reforms have been instigated in the Republic of Srpska
over almost a 10-year period. This includes for instance setting
FIGURE 2 | Utilisation (DDD/TID) and overall expenditure (€/1000
inhabitants/year) for the statins among European countries in 2007
(Italy 2008, Serbia 2008) (Godman et al., 2011a). NB: pricing: PP,
Prescriptive pricing; MF, Market Forces; MA, Mixed Approach (Box 1).
Standard EU country abbreviations have been used. ES = Catalonia.
Box 1 | Different approaches to the pricing of generics in Europe (Godman et al., 2010a).
Prescriptive pricing for generics—this can be either for the molecule (generic and originator) or just for the generic. Health Authorities
or Health Insurance Companies mandate price reductions that are necessary for generics to be reimbursed. This is either based on
originator prices pre-patent loss, reimbursed prices of generics in other European countries or a mixture of the two.
Market forces for generics—In some European countries there is no established price reduction level for the first generic or generics to
be reimbursed. This is left to market forces with a number of measures in place to accelerate price reductions.
Mixture of prescriptive pricing and market forces—In some European countries price reductions are mandated for the first generic or
generics. Market forces after that to further drive down prices.
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the reference price for drugs since 2008 at the lowest INN
molecule price (previously set as a median INN price) and
reimbursed with a 50% co-payment (previously statins were 30%
co-payment and PPIs were not reimbursed at all). At the same
time, statins were restricted to specific diseases and conditions
precisely defined by ICD-10 codes and not all doses of PPIs were
reimbursed. Whilst there was considerably increased utilization
of statins at greater than 19-fold between 2004 and 2010, these
reforms limited the increase in their reimbursed expenditures
to 4-fold during this period. These measures also helped reduce
expenditure/DDD for various PPIs between 2008 and 2010
(Markovic-Pekovic et al., 2012).
Scotland
Continued multiple demand-side measures in Scotland
(education, engineering, and economics) encouraging the
preferential prescribing of generic omeprazole and generic
statins, coupled with continued measures to lower generic prices
through increased transparency, resulted in (Bennie et al., 2012):
• Reimbursed expenditure for the PPIs Scotland in 2010 56%
below 2001 levels despite a 3 fold increase in utilization. It was
estimated that expenditure on the PPIs in Scotland would have
been GB£159 million greater in 2010 for a 5.2 million popu-
lation assuming similar utilization patterns and costs kept at
pre-patent loss prices.
• Reimbursed expenditure for the statins in 2010 in Scotland
only 7% above 2001 levels despite a 6.2-fold increase in uti-
lization. Again it was estimated that expenditure for the statins
would have been GB£290 million greater in 2010 assum-
ing similar overall utilization patterns and costs kept at the
pre-patent loss situation.
OBSERVATIONAL STUDIES ASSESSING DEMAND-SIDE MEASURES
AMONG 6 EUROPEAN COUNTRIES TO LIMIT THE PRESCRIBING OF
ARBs
The introduction of prescribing restrictions for ARBs in Austria
and Croatia restricting the prescribing of ARBs to patients intol-
erant to ACEIs limited their utilization compared with Portugal
(Table 2) where there were only limited demand-side measures
combating the marketing activities of pharmaceutical companies
(Voncˇina et al., 2011).
However, the greater intensity of follow-up of prescribing
restrictions in Croatia with regular access to patients’ histories
to check for abuse and potential fines resulted in more limited
Table 2 | % Utilisation of all Angiotensin Converting Enzyme
Inhibitors (ACEIs) vs. all renin-angiotensin inhibitor drugs among
selected EU countries (DDD basis) from 2001 to 2007 (Voncˇina et al.,
2011).
2001 2002 2003 2004 2005 2006 2007
Austria 85 82 81 79 78 76 75
Croatia 98 97 94 91 88 86 87
Portugal 80 75 71 67 64 60 56
Scotland 88 87 85 84 83 82 81
utilization of ARBs during the study period vs. Austria (Voncˇina
et al., 2011). The introduction of prescribing restrictions for
ARBs once reimbursed in the Republic of Srpska, i.e., patients
experiencing unwanted side-effects with ACEIs and only upon
specialist recommendation with active monitoring by pharma-
cists, together with 50% co-payment from only selected ARBs and
doses otherwise 100% co-payment, also limited their prescrib-
ing to just 2% of total renin-angiotensin inhibitor drugs in 2010
(Markovic-Pekovic et al., 2012).
The multiple demand side measures in Scotland (education,
engineering, and economics) also limited the prescribing of
ARBs compared to Portugal (Table 2) with its limited demand-
side measures, with ARB utilization rates similar to Austria and
Croatia. This provides guidance to health authorities in countries
who are unable to introduce prescribing restrictions. There was
also lower utilization of ARBs in Spain (Catalonia) and Sweden
compared to Portugal in recent years as a result of their multiple
demand-side measures (not shown) (Voncˇina et al., 2011).
The combination of multiple supply- and demand-side mea-
sures helped stabilize expenditure on renin-angiotensin inhibitor
drugs in Austria, Croatia, Scotland, Spain (Catalonia), and
Sweden between 2001 and 2007 when adjusted for popula-
tion sizes despite appreciable volume increases, e.g., 159% for
Scotland. However, reimbursed expenditure steadily increased in
Portugal, 41% higher in 2007 than 2001 (Voncˇina et al., 2011).
DISCUSSION
Additional reforms are essential to continue the European ide-
als given continuing pressures. As such, we consider the findings
from the various studies do provide future guidance. This is
despite the limitations of observational studies (Godman et al.,
2011a; Voncˇina et al., 2011).
General findings from the first study include more limited uti-
lization, and hence expenditure, of the PPIs and statins among
Central and Eastern European countries compared with Western
European countries (Figure 2). This is principally due to prescrib-
ing restrictions and higher patient co-payments in these countries
(Godman et al., 2011a). This endorses the need to document
ongoing reforms when comparing utilization rates across coun-
tries otherwise there could be concerns with the accuracy of the
data (Godman et al., 2011a).
More specific findings include the fact that both supply- and
demand-side reforms are essential to maximize prescribing effi-
ciency. They also demonstrate that the influence of demand-side
measures appears to be additive, with multiple demand-side mea-
sures needed to appreciably affect changes in prescribing patterns
and subsequent prescribing efficiency (Godman et al., 2011a).
This is illustrated by greater prescribing efficiency in Catalonia
(Spain), Sweden and the UK for the PPIs and statins with their
multiple and intensive demand-side measures compared with
France, Portugal and the Republic of Ireland (Figure 1) with their
more limited measures (Godman et al., 2011a). A similar situ-
ation is seen with limiting the prescribing of ARBs vs. generic
ACEIs in Scotland vs. Portugal (Table 2) (Voncˇina et al., 2011).
The prescribing of patented ARBs in Europe following the
availability of generic losartan followed a similar pattern. Limited
demand-side measures in the Republic of Ireland, Scotland, and
Frontiers in Pharmacology www.frontiersin.org June 2014 | Volume 5 | Article 106 | 6
Godman et al. Enhancing prescribing efficiency in Europe
Spain (Catalonia) resulted in no change in the subsequent utiliza-
tion of losartan post-generics (Godman et al., 2013c). This was
different in Denmark and Sweden with a significant increase in
losartan utilization following their various multifaceted demand-
side measures including education, engineering, economics, and
enforcement (Godman et al., 2013b; Hesse et al., 2013). In one
English primary care group, there was no change in the utilization
of losartan following generics with no specific demand side mea-
sures. However, losartan utilization significantly increased follow-
ing the instigation of multiple demand-side measures including
education, engineering, and economics (Martin et al., 2014). This
suggests that there is no “spill over” effect of initiatives between
classes to affect changes in prescribing habits even if the classes
are closely related (Bennie et al., 2013; Martin et al., 2014). These
findings have implications for future reforms being considered
by health authorities.
KEY CONCEPT 3 | Future reforms
Both supply- and demand-side measures are essential to improve prescrib-
ing efficiency of established medicines. Recent publications suggest that
health authorities cannot rely on any “spill over” effect to affect future pre-
scribing changes in similar classes; consequently, multiple initiatives are
needed to help health authorities achieve their goals. This includes inten-
sive follow-up of any prescribing restrictions, else health authorities could
be disappointed in the outcome.
A similar situation is seen with “enforcement.” Restricting
the prescribing of ARBs in Austria, Croatia and the Republic of
Srpska and patented statins in Austria and Norway appreciably
influenced their utilization (Table 2) (Godman et al., 2011b;
Voncˇina et al., 2011; Markovic-Pekovic et al., 2012). Prescribing
restrictions for ARBs introduced in Sweden in 2008 also further
reduced their prescribing first line (Wettermark et al., 2010).
However, the greater intensity of follow-up of ARB prescribing
restrictions in Croatia and the Republic of Srpska, and those
for patented statins in Austria, resulted in greater utilization of
generics vs. Austria and Norway respectively (Godman et al.,
2011b; Voncˇina et al., 2011; Markovic-Pekovic et al., 2012). This
was also seen with the limited impact of prescribing restrictions
for esomeprazole in Norway (Godman et al., 2011b). We believe
the limited impact observed was due to the fact that special-
ists in Norway have to verify the diagnosis and recommend
therapy before PPIs are reimbursed, and they were not subject
to these restrictions (Godman et al., 2011b). In addition, GPs
in Norway are reluctant to subsequently change prescriptions.
Timing of their introduction may also be important. The pre-
scribing restrictions recently introduced for patented statins in
Sweden had limited influence on subsequent utilization patterns
(Pettersson et al., 2012). This may be due to the fact that these
were introduced some 6 years after intensive regional activities
to encourage the preferential prescribing of generic statins
(Godman et al., 2011a; Pettersson et al., 2012). Consequently
similar to education, engineering, and economics, it is the nature
of the follow-up as well as the timing of prescribing restrictions
that appears to be important. Failure to appreciate this may result
in disappointment for health authorities.
Concentrating on one aspect of reforms, i.e., either supply or
demand side measures, but not both, can also reduce potential
efficiency gains from the availability of generics. This is illus-
trated when comparing prescribing efficiency for the statins
in Sweden and the UK (England and Scotland) vs. Germany
(Figure 2). In Germany in 2007, there was very limited utilization
of atorvastatin following the introduction of reference pricing
for the class in 2003 at just 2% of overall statin utilization with
rosuvastatin not available (Godman et al., 2009). This compares
with 21 and 33% respectively on a DDD basis for the apprecia-
bly more expensive atorvastatin and rosuvastatin in Sweden and
England in 2007 (Godman et al., 2012b). However, compara-
tive expenditures appear similar or greater in Germany compared
with Sweden or England due to higher expenditure/DDD for
simvastatin (Figure 2). In Korea, just concentrating on cutting
pharmaceutical prices without introducingmultiple demand-side
measures also failed to produce the desired efficiency gains when
treating hyperlipidaemia (Kwon et al., 2013).
One aspect of a lower price for generic statins is a lowering of
the threshold to prevent coronary vascular disease. Draft guidance
in the UK, which is under review, is recommending that statins
should now be offered to people who have a 10 per cent or greater
10-year risk of developing CVD (down from 20%) (NICE, 2014).
We are also now seeing countries appearing to learn from each
other as resources pressures grow (Godman et al., 2011a). This
will continue given continued resource pressures.
However, there are classes where it can be difficult for pay-
ers to introduce demand-side measures to appreciably increase
the prescribing of generics. This is seen with atypical antipsy-
chotic drugs for treating schizophrenia and bipolar disease where
experts as well as national authorities suggest pharmacotherapeu-
tic treatments should be tailored to individual patients (Godman
et al., 2013d). Recent cross national studies have shown there is
a consistent decrease in risperidone utilization as a percentage
of all selected atypical antipsychotics (DDD basis) following the
availability of generics among a number of European countries
(Godman et al., 2013d,e,f). Consequently, health authorities need
to wait until more atypical antipsychotic drugs become available
as generics before they see significant reductions in expenditure.
This is already happening (Godman et al., 2013d).
KEY CONCEPT 4 | Tailoring of treatments
There are certain classes such as atypical antipsychotic drugs where treat-
ment should be tailored to the individual patient. In these circumstances, it
is difficult for health authorities to instigate multiple demand-side measures
to affect changes in physician prescribing habits and they need to wait till
more drugs become available as generics to realize appreciable savings.
We accept there are limitations with observational studies.
However, we believe the consistency of the findings across the
various classes will be of interest to health authorities as they
plan future supply and demand side measures to further improve
their prescribing efficiency. This includes the fact that multiple
demand-side measures are needed to affect changes in physician
prescribing patterns. Otherwise there is limited change. There
also appears to be no “spill over” effect of initiatives between
classes even if these are closely related. The timing and follow-up
of prescribing restrictions is also important else health authori-
ties could be disappointed with the outcome of such restrictions.
Finally, there are some classes where it is difficult to introduce
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multiple demand-side measures. This includes pharmacotherapy
of schizophrenia where treatments should be individualized.
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